Sygnature Discovery

Sygnature Discovery will be attending the 39th ACS National Medicinal Chemistry Symposium (NMCS 2026), a biennial meeting that brings together industry and academic chemists to examine how these challenges are being addressed in practice, from small molecule therapeutics to targeted protein degradation and covalent inhibitors. We’ll be there to share perspectives shaped by hands on medicinal chemistry and integrated discovery work, with an emphasis on feasibility, risk, and making sound choices early in a program. 👥 Meet Allan Jordan (アラン ジョーダン), Ridwan Islam, M. Pharm., Ph.D., and Stuart Onions at Booth #20. Allan and Stuart will be presenting posters: – Direct to Discovery: Extending Direct to Biology paradigms to accelerate drug discovery (Allan Jordan) – Discovery of Opelconazole (Stuart Onions) ✨ We’re also hosting a private event on June 1st at 7pm EDT - visit our booth or click the link in the comments to secure your free invite (limited capacity). Join the conversation. #Pharma #DrugDiscovery #Biotech #CRO

The best compounds aren’t exceptional in one assay. They’re balanced across many. In early discovery, it’s easy to chase the strongest single signal - potency, a clean readout, a standout number. But compounds that progress are often the ones that are “just right” across multiple dimensions. That’s why effective teams focus on multiparametric decision making, considering: • Functional biochemical activity • Cellular relevance • Early developability and DMPK signals Looking at these data together helps teams rank compounds more confidently and prioritise those with balanced profiles, even when no single result looks dramatic on its own. This is how better decisions get made earlier, without over optimising the wrong signal. 👉 Read the full blog or watch the recorded talk on YouTube: https://hubs.la/Q04gdNPM0 #Pharma #DrugDiscovery #Biotech #CRO

***27th May, Leveraging CRO Partnerships to De-Risk and Accelerate Biotech Fundraising **** Excited to announce the line-up for our panel discussion next week for the 2nd Edition of our "Stories of Drug Discovery Success" event series. If you are interested in attending please sign-up via https://lnkd.in/e6dkqbvD John Isaac, Slingshot Therapeutics Benedict CS Cross, Stick Therapeutics Tom McCarthy, Molecule to Medicine Allan Jordan (アラン ジョーダン), Sygnature Discovery Stuart Onions, Sygnature Discovery

Standard Direct-to-Biology workflows often focus primarily on affinity or efficacy measurements from CRMs, overlooking the broader value of this rich data source. To unlock this potential, we have expanded the approach. 🧪 Our Direct‑to‑Discovery model combines automated high‑throughput synthesis, flexible bioassay integration, real‑time structural insight, and early DMPK profiling. Together, these integrated strengths enable the generation of biological, structural, and property data directly from crude reaction mixtures, supporting faster and more informed decision‑making. It’s not just about capability though, it’s about integrating expertise to apply the right strategy at the right time. ✨Discover our difference #Pharma #DrugDiscovery #Biotech #CRO

📄 A new peer reviewed publication co authored by Sygnature’s DINH Chau Phi examines the osteogenic, antiresorptive, and toxicological profile of α mangostin using both MC3T3 E1 pre osteoblast cells and medaka in vivo models. By characterising biological activity alongside dose dependent toxicity, the study highlights how early, integrated evaluation can help discovery teams make more informed decisions before progression. The work was published in the Korean Journal of Physiology & Pharmacology: “Osteogenic, antiresorptive, and toxicological evaluation of alpha mangostin in MC3T3 E1 cells and medaka fish.” 👉 Read the full article: https://hubs.la/Q04fCrNZ0 #Pharma #DrugDiscovery #Biotech #CRO

CNS biology is rarely driven by a single neurotransmitter. Dopamine, serotonin, noradrenaline, glutamate and their metabolites are constantly interacting to shape what we see at a functional level. If you only look at one signal at a time, it’s easy to miss what’s really going on. With intracerebral microdialysis, we can measure multiple neurotransmitters and metabolites simultaneously from a single sample. That gives a much clearer picture of how interconnected pathways respond to a drug, in real time and in the same experiment. And when that multiplexed neurochemistry is interpreted alongside behaviour and PK/PD, it opens the door to a deeper understanding of mechanism—and better translational insight. More analytes. One sample. Clearer CNS insight. Learn more about our intracerebral microdialysis capability: https://hubs.la/Q04gprFc0 #CNS #Microdialysis #DrugDiscovery #BehaviouralNeuroscience

✨ Direct‑to‑Biology is not just about going faster, it’s about making better decisions, earlier. Our Direct‑to‑Discovery approach builds on Direct‑to‑Biology by integrating chemistry, biology, structural biology, and DMPK earlier in the process. This isn't just about going faster; it's about changing the cadence of discovery. 👉 Curious where Direct‑to‑Discovery could add the most value in your program? Get in touch. #Biotech #Pharma #DrugDiscovery #CRO #DirectToBiology

*** 27th May, Stories of Drug Discovery Success 2nd Edition** Very excited to announce Sygnature Discovery's scientific event entitled "De-Risking Biotech Fundraising Through Smarter R&D Partnerships". The evening will begin with two insightful talks from: 1. Benedict CS Cross, CEO Stick Therapeutics 2. John Isaac, CSO Slingshot Therapeutics Followed by a panel session to discuss "Leveraging CRO Partnerships to De-Risk and Accelerate Biotech Fundraising". If you are interested in attending, please register via this link: https://lnkd.in/e6dkqbvD

🤝 From collaboration to clinic Our work with Corcept Therapeutics began over a decade ago as an integrated drug discovery collaboration spanning medicinal chemistry, computational design, biology, DMPK and in vivo research. Together, we navigated the challenges of designing selective glucocorticoid receptor modulators and it’s this work that led to relacorilant entering development. We’ve captured the story of this collaboration in our case study, including the approaches, challenges and innovations along the way. Read the full case study: https://hubs.la/Q04gnXTV0 We’re proud to have played a part in this journey and congratulate everyone involved on reaching this significant milestone. #Pharma #DrugDiscovery #Biotech #CRO